SteroTherapeutics is pursuing a novel drug therapy for major diseases related to metabolic syndrome, which afflicts 35% of the US adult population. Cushing's syndrome is caused by elevated levels of a hormone called cortisol, which can promote obesity, diabetes, hypertension, cardiovascular disease, and immune dysfunction. Cushing's, which is an orphan disease, is poorly served by currently available therapies that only modestly effective and have substantial side effects. SteroTherapeutics signed the CRADA agreement with NIH to develop a novel treatment for Cushing syndrome patients.
The second metabolic disease product, our company is developing is for the treatment of Primary Sclerosing Cholingitis (PSC). PSC is a rare, heterogeneous, idiopathic, inflammatory disorder of the bile ducts resulting in strictures of the intrahepatic and /or extrahepatic bile ducts. Although the great majority of PSC patients have inflammatory bowel disease (IBD), only ~ 5% of IBD patients will develop PSC, the underlying causes of the association remains poorly understood.
The company is also developing a treatment for multiple myeloma with a highly selective novel matrix metallaoproteinase-13 (MMP-13) inhibitor licensed from the Moffitt Cancer Center/ FAU with no apparent off-target MMP inhibition. Thereby solving the foremost problem with the class of drugs with no collagenolysis and no multiple skeltal syndrome.
For any inquiries or questions please call: 267-300-0010 or fill out the following form
3805 Old Easton Rd
Doylestown, PA 18902
We are always looking for motivated, ambitious, talented and passionate professionals to join our team. If you're interested in a position with us,
Please email us at email@example.com